ö°áÇ̼º ºóÇ÷ Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ä¡·á À¯Çüº°, ¿¬·É´ëº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)
Iron Deficiency Anemia Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy), By Age Group, By End-user, By Region, And Segment Forecasts, 2023 - 2030
»óǰÄÚµå : 1363099
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2023³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,443,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,862,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,700,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ö°áÇ̼º ºóÇ÷ Ä¡·á ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼¼°è ö°áÇ̼º ºóÇ÷ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 80¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 7.6%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ù°æ Áß ºñÁ¤»óÀûÀÎ ´Ù·®ÀÇ ÃâÇ÷°ú ºÐ¸¸ ÈÄ ÃâÇ÷ÀÇ Áõ°¡´Â ÀþÀº ¿©¼ºµéÀÇ IDA ¿ä¹ý äÅ÷üÀ» ³ôÀÌ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ¿©¼ºÀÇ ¿µ¾ç °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ºñ°æ±¸ ¿µ¾ç º¸ÃæÁ¦ÀÇ ¹ßÀü, ½ÅÁ¦Ç° Ãâ½Ã µîÀÌ Ã¶°áÇ̼º ºóÇ÷(IDA) Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

2023³â 3¿ù¿¡ ¾÷µ¥ÀÌÆ®µÈ ±¹¸³ÀÇÇеµ¼­°ü º¸°í¼­¿¡ µû¸£¸é ¿ù°æÅëÀÇ ¿¬°£ À¯º´·üÀº ¿©¼º 1,000¸í´ç 53¸íÀ̸ç, 2018³â 6¿ù ±¹¸³ÀÇÇеµ¼­°üÀÌ ¹ßÇ¥ÇÑ ¶Ç ´Ù¸¥ ³í¹®¿¡ µû¸£¸é Æó°æ±â ¿¬·É´ëÀÇ IDA »ç·ÊÀÇ ¾à 5-10%´Â ¿ù°æÅë(¿ù°æÇ÷ÀÌ ¸¹À½) µî ¿ù°æ Àå¾Ö¿¡ ±âÀÎÇÑ´Ù°í ÇÕ´Ï´Ù. »ý¸®ºÒ¼ø(»ý¸®Ç÷ÀÌ ¸¹À½)°ú °°Àº ¿ù°æ Àå¾Ö°¡ ¿øÀÎÀ̶ó°í ÇÕ´Ï´Ù. ¶ÇÇÑ, Æó°æ±â ¿©¼ºµé »çÀÌ¿¡¼­ ¿µ¾ç öºÐ °áÇÌÀÌ ÀÌ¹Ì ³Î¸® ÆÛÁ® ÀÖ´Â °³¹ßµµ»ó±¹¿¡¼­´Â ¿ù°æÅëÀÌ ¾ÇÈ­ ¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ¿© ½É°¢ÇÑ ºóÇ÷À» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù.

±¹¹ÎÀÇ ÀÎ½Ä Áõ°¡, ¿©¼º ¿µ¾ç °Ç°­¿¡ ´ëÇÑ Áö¿ª Á¤ºÎÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê, ºñ°æ±¸ ¿µ¾ç º¸ÃæÁ¦ÀÇ ¹ßÀü, ½ÅÁ¦Ç° Ãâ½Ã µîÀº ¼¼°è IDA ¿ä¹ý ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Àεµ¿¡¼­´Â 2023³â 2¿ù Äɶö¶ó ÁÖ Á¤ºÎ°¡ Áß¾Ó Á¤ºÎÀÇ ºóÇ÷ ¹«Å©Æ® ¹Ù¶ù(Anemia Mukt Bharat) ÇÁ·Î±×·¥¿¡ Ãß°¡ÇÏ¿© ÀÌ´Ï¼ÅÆ¼ºê¸¦ ½ÃÀÛÇß½À´Ï´Ù. ÀÌ Ä·ÆäÀÎÀº 6°³¿ù À̳»¿¡ ÁÖ Àüü¿¡¼­ ¾à 1,300¸¸ ¸íÀÇ ¿©¼º¿¡°Ô µµ´ÞÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çß½À´Ï´Ù. ºóÇ÷ÀÇ ºÎ´ãÀ» ÁÙÀ̱â À§ÇÑ ´Ü°èº° °³ÀÔÀ» Å×½ºÆ®ÇÏ°í ½ÃÇàÇϱâ À§ÇØ °¡°¡È£È£ ¹æ¹® Ä·ÆäÀÎÀÌ ÁøÇàµÇ¾ú½À´Ï´Ù.

¾÷°è ´ë±â¾÷µéÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °­È­Çϱâ À§ÇØ Á¦ÈÞ ¹× Àμö¿¡ Èû¾²°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 11¿ù CSL Vifor¿Í Fresenius Kabi´Â Á¤¸ÆÁÖ»ç öºÐÁ¦ Ferinject°¡ Áß±¹ NMPA·ÎºÎÅÍ ¼ºÀΠȯÀÚÀÇ Ã¶ºÐ °áÇÌÁõ Ä¡·áÁ¦·Î ½ÂÀÎ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. Æä¸°Á§Æ®´Â °æ±¸¿ë Á¦Á¦°¡ È¿°ú°¡ ¾ø°Å³ª ºÎÀûÇÕÇÑ °æ¿ì ¶Ç´Â ÀÓ»óÀûÀ¸·Î ½Å¼ÓÇÑ Ã¶ºÐ Åõ¿©°¡ ÇÊ¿äÇÑ °æ¿ì¿¡ »ç¿ëµË´Ï´Ù. ´ç½Ã ¾ç»ç´Â 2023³â »ó¹Ý±â¿¡ Æä¸µÁ§Æ® ÆÇ¸Å¸¦ ½ÃÀÛÇÒ °èȹÀ̾úÀ¸¸ç, À̹ø ½ÂÀÎÀ¸·Î 85°³±¹¿¡¼­ ÆÇ¸Å Çã°¡¸¦ ȹµæÇϰí 2024³â 1¿ù NRDL¿¡ »óÀåÇÒ ¿¹Á¤À̾ú½À´Ï´Ù. ÀÌ´Â ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϰí Àü ¼¼°èÀûÀ¸·Î Æä¸µÁ§Æ®¿¡ ´ëÇÑ È¯ÀÚ Á¢±Ù¼ºÀ» È®´ëÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ ÀǹÌÇÕ´Ï´Ù. ¶ÇÇÑ, 2021³â 7¿ù, Sandoz´Â ¹Ì±¹¿¡¼­ ö°áÇ̼º ºóÇ÷ Ä¡·á Áß ÃÖÃÊÀÇ °í¿ë·® öºÐÁ¦Á¦ Á¦³×¸¯ÀÎ ºñ¿ë È¿À²ÀûÀÎ Æä¸£¸ñ½ÃÅç ÁÖ»çÁ¦¸¦ Ãâ½ÃÇÏ¿´½À´Ï´Ù.

ö°áÇ̼º ºóÇ÷ Ä¡·á ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

Á¦4Àå Ä¡·á À¯Çü ÇüÅ ºñÁö´Ï½º ºÐ¼®

Á¦5Àå ¿¬·ÉÃþº° ºñÁö´Ï½º ºÐ¼®

Á¦6Àå ÃÖÁ¾»ç¿ëÀÚº° ºñÁö´Ï½º ºÐ¼®

Á¦7Àå Áö¿ªº° ºñÁö´Ï½º ºÐ¼®

Á¦8Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Iron Deficiency Anemia Therapy Market Growth & Trends:

The global iron deficiency anemia therapy market size is expected to reach USD 8.06 billion by 2030, as per a new study by Grand View Research, Inc.. The market is projected to grow at a CAGR of 7.6% from 2023 to 2030. Rising cases of abnormally heavy bleeding during menstruation and post-partum hemorrhage are some major factors increasing the adoption rate of IDA therapy in young women. Moreover, rising awareness for women's nutritional health, advancing parenteral nutrition supplements, and novel product launches are some key drivers fueling the market growth for iron deficiency anemia (IDA) therapy.

According to a National Library of Medicine report updated in March 2023, the annual prevalence of menorrhagia is 53 per 1,000 women. Another article published by the National Library of Medicine in June 2018 states that menstrual disorders such as menorrhagia (heavy menstrual blood loss) contribute to approximately 5-10% of cases of IDA in the perimenopausal age group. Moreover, in developing countries where nutritional iron deficiency is already prevalent among perimenopausal women, menorrhagia is an exacerbating factor, leading to severe anemia.

Rising awareness among people and strategic initiatives by regional governments for women's nutritional health, advancing parenteral nutrition supplements, and novel product launches are some of the key driving factors for the global IDA therapy market growth. For instance, in February 2023, in India, the Kerala state government launched its initiative in addition to the Centre's Anaemia Mukt Bharat program. The campaign aimed to reach around 13 million women across the state within six months. A door-to-door campaign was conducted to test and implement graded interventions to reduce the burden of anemia.

Industry leaders are involved in collaborations & acquisitions to enhance their product portfolios. For instance, in November 2022, CSL Vifor and Fresenius Kabi announced that Ferinject, an intravenous iron therapy, had received approval from China's NMPA for treating iron deficiency in adult patients. Ferinject is indicated for cases where oral preparations are ineffective or unsuitable or when rapid iron delivery is clinically necessary. At the time, the companies planned to commence marketing Ferinject in the first half of 2023, with the approval marking its marketing authorization in 85 countries, along with an anticipated NRDL listing in January 2024. This represents an opportunity for enhanced market presence and expanded patient access to Ferinject globally. Similarly, in July 2021, Sandoz launched a cost-effective Ferumoxytol injection, the first generic intravenous high-dosage iron for treating IDA in the U.S.

Iron Deficiency Anemia Therapy Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Therapy Type Business Analysis

Chapter 5. Age Group Business Analysis

Chapter 6. End-User Business Analysis

Chapter 7. Regional Business Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â